{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hRPC&page=19",
    "query": {
      "intervention": "hRPC",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 862,
    "total_pages": 87,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hRPC&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hRPC&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T12:46:53.813Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02500901",
      "title": "Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul Mathew, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2016-03",
      "completion_date": "2016-05-10",
      "has_results": true,
      "last_update_posted_date": "2019-10-21",
      "last_synced_at": "2026-10-25T12:46:53.813Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02500901"
    },
    {
      "nct_id": "NCT06039371",
      "title": "Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Adenocarcinoma",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Testosterone Cypionate",
          "type": "DRUG"
        },
        {
          "name": "Radioconjugate",
          "type": "OTHER"
        },
        {
          "name": "Dual X-ray Absorptiometry",
          "type": "PROCEDURE"
        },
        {
          "name": "Gallium Ga 68-PSMA-617",
          "type": "OTHER"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Single Photon Emission Computed Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 69,
      "start_date": "2024-05-21",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-10-25T12:46:53.813Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06039371"
    },
    {
      "nct_id": "NCT05047536",
      "title": "KZR-261 in Subjects With Advanced Solid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced/Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "KZR-261",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kezar Life Sciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2021-09-30",
      "completion_date": "2025-01-17",
      "has_results": true,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-10-25T12:46:53.813Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05047536"
    },
    {
      "nct_id": "NCT00133900",
      "title": "Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hormone Refractory Prostate Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Phlebotomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Immunicon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 276,
      "start_date": "2004-12",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2009-07-28",
      "last_synced_at": "2026-10-25T12:46:53.813Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00133900"
    },
    {
      "nct_id": "NCT05917470",
      "title": "A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ONCT-534",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncternal Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 21,
      "start_date": "2023-09-20",
      "completion_date": "2024-09-12",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-10-25T12:46:53.813Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Detroit, Michigan • Omaha, Nebraska + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05917470"
    },
    {
      "nct_id": "NCT01020305",
      "title": "Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostatic Neoplasms",
        "Castrate-resistant Prostate Cancer (CRPC)",
        "Androgen-insensitive Prostate Cancer",
        "Hormone-refractory Prostate Cancer",
        "Metastatic Disease"
      ],
      "interventions": [
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Casodex (bicalutamide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sandy Srinivas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 5,
      "start_date": "2009-10",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2014-10-13",
      "last_synced_at": "2026-10-25T12:46:53.813Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01020305"
    },
    {
      "nct_id": "NCT02963051",
      "title": "A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Copper",
          "type": "DRUG"
        },
        {
          "name": "Disulfiram",
          "type": "DRUG"
        },
        {
          "name": "Copper gluconate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel George, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2017-07-11",
      "completion_date": "2020-02-01",
      "has_results": false,
      "last_update_posted_date": "2021-09-16",
      "last_synced_at": "2026-10-25T12:46:53.813Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02963051"
    },
    {
      "nct_id": "NCT06780670",
      "title": "Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Investigators choice of SoC",
          "type": "DRUG"
        },
        {
          "name": "AAA817",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 443,
      "start_date": "2025-02-27",
      "completion_date": "2033-07-19",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-25T12:46:53.813Z",
      "location_count": 35,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06780670"
    },
    {
      "nct_id": "NCT02987829",
      "title": "Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castrate-resistant Prostate Cancer",
        "Adenocarcinoma, Prostate"
      ],
      "interventions": [
        {
          "name": "TRC253",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tracon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 72,
      "start_date": "2017-05-23",
      "completion_date": "2020-11-09",
      "has_results": true,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-10-25T12:46:53.813Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02987829"
    },
    {
      "nct_id": "NCT02003924",
      "title": "Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nonmetastatic Castration-Resistant Prostate Cancer",
        "Prostate Cancer",
        "Cancer of the Prostate"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1401,
      "start_date": "2013-10-31",
      "completion_date": "2025-11-28",
      "has_results": true,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-10-25T12:46:53.813Z",
      "location_count": 37,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Orange, California + 27 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Luis Obispo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02003924"
    }
  ]
}